Point-of-care heart failure platform: where are we now and where are we going to?

Berezin, Alexander Е.; Berezin, Alexander A.

doi:10.1080/14779072.2022.2080657

Cited by 3 publications

(1 citation statement)

References 86 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biomarker-guided management of HF as part of the POC HF platform, comprising personal consultation, optimal comorbidity care, and concise HF diagnostic and treatment algorithms, seems to be a promising strategy as well as an effective tool that has been partially implemented in current HF guidelines [8]. The new 2021 guidelines of the European Society of Cardiology (ESC) for the diagnosis and treatment of acute and chronic HF and the 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America (AHA/ACC/HFSA) guidelines report strong agreement in the use of natriuretic peptides (NPs) in the diagnosis, prediction, and management of HF, although only the 2022 AHA/ACC/HFSA guidelines provide alternative biomarkers (galectin-3, soluble suppressor tumorigenisity-2) for risk stratification and prediction of outcomes [9,10].…”

Section: Introductionmentioning

confidence: 99%

Biomarkers in Heart Failure: From Research to Clinical Practice

Berezin

2022

Ann Lab Med

Self Cite

View full text Add to dashboard Cite

The aim of this narrative review is to summarize contemporary evidence on the use of circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker model for clinical use in personalized point-of-care HF management. We discuss the reported biomarkers of HF classified into clusters, including myocardial stretch and biomechanical stress; cardiac myocyte injury; systemic, adipocyte tissue, and microvascular inflammation; cardiac fibrosis and matrix remodeling; neurohumoral activation and oxidative stress; impaired endothelial function and integrity; and renal and skeletal muscle dysfunction. We focus on the benefits and drawbacks of biomarker-guided assistance in daily clinical management of patients with HF. In addition, we provide clear information on the role of alternative biomarkers and future directions with the aim of improving the predictive ability and reproducibility of multiple biomarker models and advancing genomic, transcriptomic, proteomic, and metabolomic evaluations.

show abstract

Section: Introductionmentioning

confidence: 99%

Biomarkers in Heart Failure: From Research to Clinical Practice

Berezin

2022

Ann Lab Med

Self Cite

View full text Add to dashboard Cite

show abstract

Diagnostic and predictive abilities of myokines in patients with heart failure

Berezin,

Berezina,

Hoppe

et al. 2024

Advances in Protein Chemistry and Structural Biology

View full text Add to dashboard Cite

Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure

Berezin

Obradovic²,

Fushtey

et al. 2023

JCDD

View full text Add to dashboard Cite

The aim of this study was to determine the discriminative value of irisin for acutely decompensated heart failure (ADHF) in type 2 diabetes mellitus (T2DM) patients with chronic HF. We included 480 T2DM patients with any phenotype of HF and followed them for 52 weeks. Hemodynamic performances and the serum levels of biomarkers were detected at the study entry. The primary clinical end-point was ADHF that led to urgent hospitalization. We found that the serum levels of N-terminal natriuretic pro-peptide (NT-proBNP) were higher (1719 [980–2457] pmol/mL vs. 1057 [570–2607] pmol/mL, respectively) and the levels of irisin were lower (4.96 [3.14–6.85] ng/mL vs. 7.95 [5.73–9.16] ng/mL) in ADHF patients than in those without ADHF. The ROC curve analysis showed that the estimated cut-off point for serum irisin levels (ADHF versus non-ADHF) was 7.85 ng/mL (area under curve [AUC] = 0.869 (95% CI = 0.800–0.937), sensitivity = 82.7%, specificity = 73.5%; p = 0.0001). The multivariate logistic regression yielded that the serum levels of irisin < 7.85 ng/mL (OR = 1.20; p = 0.001) and NT-proBNP > 1215 pmol/mL (OR = 1.18; p = 0.001) retained the predictors for ADHF. Kaplan–Meier plots showed a significant difference of clinical end-point accumulations in patients with HF depending on irisin levels (<7.85 ng/mL versus ≥7.85 ng/mL). In conclusion, we established that decreased levels of irisin were associated with ADHF presentation in chronic HF patients with T2DM independently from NT-proBNP.

show abstract

Point-of-care heart failure platform: where are we now and where are we going to?

Cited by 3 publications

References 86 publications

Biomarkers in Heart Failure: From Research to Clinical Practice

Biomarkers in Heart Failure: From Research to Clinical Practice

Diagnostic and predictive abilities of myokines in patients with heart failure

Low Plasma Levels of Irisin Predict Acutely Decompensated Heart Failure in Type 2 Diabetes Mellitus Patients with Chronic Heart Failure

Contact Info

Product

Resources

About